These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Efficacy and safety of fluticasone propionate 44 microg/salmeterol 21 microg administered in a hydrofluoroalkane metered-dose inhaler as an initial asthma maintenance treatment. Nelson HS; Wolfe JD; Gross G; Greos LS; Baitinger L; Scott C; Dorinsky P Ann Allergy Asthma Immunol; 2003 Sep; 91(3):263-9. PubMed ID: 14533658 [TBL] [Abstract][Full Text] [Related]
5. Comparison of patient-reported outcomes during treatment with adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler versus fixed-dose fluticasone propionate/salmeterol dry powder inhaler in patients with asthma. O'Connor RD; Patrick DL; Parasuraman B; Martin P; Goldman M J Asthma; 2010 Mar; 47(2):217-23. PubMed ID: 20170333 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of salmeterol/fluticasone propionate delivered via a hydrofluoroalkane metered dose inhaler in Chinese patients with moderate asthma poorly controlled with inhaled corticosteroids. You-Ning L; Humphries M; Du X; Wang L; Jiang J Int J Clin Pract; 2005 Jul; 59(7):754-9. PubMed ID: 15963199 [TBL] [Abstract][Full Text] [Related]
7. Salmeterol/fluticasone propionate (50/500 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma. Aubier M; Pieters WR; Schlösser NJ; Steinmetz KO Respir Med; 1999 Dec; 93(12):876-84. PubMed ID: 10653049 [TBL] [Abstract][Full Text] [Related]
9. Fluticasone propionate HFA-134a pressurized metered-dose inhaler in adolescents and adults with moderate to severe asthma. Pinnas JL; Noonan MJ; Weinstein SF; Chervinsky P; Scott CA; Herje NE; Wu W; Crim C J Asthma; 2005 Dec; 42(10):865-71. PubMed ID: 16393726 [TBL] [Abstract][Full Text] [Related]
10. Tolerability of a salmeterol xinafoate/fluticasone propionate hydrofluoroalkane metered-dose inhaler in adolescent and adult patients with persistent asthma: a 52-week, open-label, stratified, parallel-group, multicenter study. Cowie RL; Boulet LP; Keith PK; Scott-Wilson CA; House KW; Dorinsky PM Clin Ther; 2007 Jul; 29(7):1390-402. PubMed ID: 17825690 [TBL] [Abstract][Full Text] [Related]
11. Inhaled salmeterol/fluticasone propionate combination: a review of its use in persistent asthma. Markham A; Jarvis B Drugs; 2000 Nov; 60(5):1207-33. PubMed ID: 11129128 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients. Daley-Yates PT; Mehta R; Chan RH; Despa SX; Louey MD J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):279-89. PubMed ID: 24074143 [TBL] [Abstract][Full Text] [Related]
13. Salmeterol and fluticasone propionate (50/250 microg) administered via combination Diskus inhaler: as effective as when given via separate Diskus inhalers. Chapman KR; Ringdal N; Backer V; Palmqvist M; Saarelainen S; Briggs M Can Respir J; 1999; 6(1):45-51. PubMed ID: 10202220 [TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of combination salmeterol (50 microg)/fluticasone propionate (500 microg) inhalation twice daily via accuhaler in Chinese patients with COPD. Zheng JP; Yang L; Wu YM; Chen P; Wen ZG; Huang WJ; Shi Y; Wang CZ; Huang SG; Sun TY; Wang GF; Xiong SD; Zhong NS Chest; 2007 Dec; 132(6):1756-63. PubMed ID: 17951625 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of fluticasone propionate/salmeterol HFA 134A MDI in patients with mild-to-moderate persistent asthma. Pearlman DS; Peden D; Condemi JJ; Weinstein S; White M; Baitinger L; Scott C; Ho SY; House K; Dorinsky P J Asthma; 2004; 41(8):797-806. PubMed ID: 15641629 [TBL] [Abstract][Full Text] [Related]
16. Fluticasone propionate/salmeterol hydrofluoroalkane via metered-dose inhaler with integrated dose counter: Performance and patient satisfaction. Sheth K; Wasserman RL; Lincourt WR; Locantore NW; Carranza-Rosenzweig J; Crim C Int J Clin Pract; 2006 Oct; 60(10):1218-24. PubMed ID: 16981966 [TBL] [Abstract][Full Text] [Related]
17. Hypothalamic-pituitary-adrenal axis effects of mometasone furoate/formoterol fumarate vs fluticasone propionate/salmeterol administered through metered-dose inhaler. Kosoglou T; Hubbell J; Cutler DL; Johnson-Levonas AO; Xu D; Kantesaria BS; Kim K; Miller SD Chest; 2013 Dec; 144(6):1795-1802. PubMed ID: 24077095 [TBL] [Abstract][Full Text] [Related]
18. Inhaled salmeterol/fluticasone propionate: a review of its use in asthma. Reynolds NA; Lyseng-Williamson KA; Wiseman LR Drugs; 2005; 65(12):1715-34. PubMed ID: 16060707 [TBL] [Abstract][Full Text] [Related]
19. Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder inhaler in asthma patients. Busse WW; Shah SR; Somerville L; Parasuraman B; Martin P; Goldman M J Allergy Clin Immunol; 2008 Jun; 121(6):1407-14, 1414.e1-6. PubMed ID: 18455221 [TBL] [Abstract][Full Text] [Related]
20. Fluticasone propionate and salmeterol administered via Diskus compared with salmeterol or fluticasone propionate alone in patients suboptimally controlled with short-acting beta2-agonists. Murray J; Rosenthal R; Somerville L; Blake K; House K; Baitinger L; VanderMeer A; Dorinsky P Ann Allergy Asthma Immunol; 2004 Oct; 93(4):351-9. PubMed ID: 15521371 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]